32205957|t|ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs.
32205957|a|A. ACUTE HYPERCAPNIC RESPIRATORY FAILURE A1. Acute Exacerbation of COPD: Recommendations: NIV should be used in management of acute exacerbation of COPD in patients with acute or acute-on-chronic respiratory acidosis (pH = 7.25-7.35). (1A) NIV should be attempted in patients with acute exacerbation of COPD (pH <7.25 & PaCO2 >= 45) before initiating invasive mechanical ventilation (IMV) except in patients requiring immediate intubation. (2A). Lower the pH higher the chance of failure of NIV. (2B) NIV should not to be used routinely in normo- or mildly hyper-capneic patients with acute exacerbation of COPD, without acidosis (pH > 7.35). (2B) A2. NIV in ARF due to Chest wall deformities/Neuromuscular diseases: Recommendations: NIV may be used in patients of ARF due to chest wall deformity/Neuromuscular diseases. (PaCO2 >= 45) (UPP) A3. NIV in ARF due to Obesity hypoventilation syndrome (OHS): Recommendations: NIV may be used in AHRF in OHS patients when they present with acute hypercapnic or acute on chronic respiratory failure (pH 45). (3B) NIV/CPAP may be used in obese, hypercapnic patients with OHS and/or right heart failure in the absence of acidosis. (UPP) B. NIV IN ACUTE HYPOXEMIC RESPIRATORY FAILURE: B1. NIV in Acute Cardiogenic Pulmonary Oedema: Recommendations: NIV is recommended in hospital patients with ARF, due to Cardiogenic pulmonary edema. (1A). NIV should be used in patients with acute heart failure/ cardiogenic pulmonary edema, right from emergency department itself. (1B) Both CPAP and BiPAP modes are safe and effective in patients with cardiogenic pulmonary edema. (1A). However, BPAP (NIV-PS) should be preferred in cardiogenic pulmonary edema with hypercapnia. (3A) B2. NIV in acute hypoxemic respiratory failure: Recommendations: NIV may be used over conventional oxygen therapy in mild early acute hypoxemic respiratory failure (P/F ratio <300 and >200 mmHg), under close supervision. (2B) We strongly recommend against a trial of NIV in patients with acute hypoxemic failure with P/F ratio <150. (2A) B3. NIV in ARF due to Chest Trauma: Recommendations: NIV may be used in traumatic flail chest along with adequate pain relief. (3B) B4. NIV in Immunocompromised Host: Recommendations: In Immunocompromised patients with early ARF, we may consider NIV over conventional oxygen. (2B). B5. NIV in Palliative Care: Recommendations: We strongly recommend use of NIV for reducing dyspnea in palliative care setting. (2A) B6. NIV in post-operative cases: Recommendations: NIV should be used in patients with post-operative acute respiratory failure. (2A) B6a. NIV in abdominal surgery: Recommendations: NIV may be used in patients with ARF following abdominal surgeries. (2A) B6b. NIV in bariatric surgery: Recommendations: NIV may be used in post-bariatric surgery patients with pre-existent OSA or OHS. (3A) B6c. NIV in Thoracic surgery: Recommendations: In cardiothoracic surgeries, use of NIV is recommended post operatively for acute respiratory failure to improve oxygenation and reduce chance of reintubation. (2A) NIV should not be used in patients undergoing esophageal surgery. (UPP) B6d. NIV in post lung transplant: Recommendations: NIV may be used for shortening weaning time and to avoid re-intubation following lung transplantation. (2B) B7. NIV during Procedures (ETI/Bronchoscopy/TEE/Endoscopy): Recommendations: NIV may be used for pre-oxygenation before intubation. (2B) NIV with appropriate interface may be used in patients of ARF during Bronchoscopy/Endoscopy to improve oxygenation. (3B) B8. NIV in Viral Pneumonitis ARDS: Recommendations: NIV cannot be considered as a treatment of choice for patients with acute respiratory failure with H1N1 pneumonia. However, it may be reasonable to use NIV in selected patients with single organ involvement, in a strictly controlled environment with close monitoring. (2B) B9. NIV and Acute exacerbation of Pulmonary Tuberculosis: Recommendations: Careful use of NIV in patients with acute Tuberculosis may be considered, with effective infection control precautions to prevent air-borne transmission. (3B) B10. NIV after planned extubation in high risk patients: Recommendation: We recommend that NIV may be used to wean high risk patients from invasive mechanical ventilation as it reduces re-intubation rate. (2B) B11. NIV for respiratory distress post extubation: Recommendations: We recommend that NIV therapy should not be used to manage respiratory distress post-extubation in high risk patients. (2B) C. APPLICATION OF NIV: Recommendation: Choice of mode should be mainly decided by factors like disease etiology and severity, the breathing effort by the patient and the operator familiarity and experience. (UPP) We suggest using flow trigger over pressure triggering in assisted modes, as it provides better patient ventilator synchrony. Especially in COPD patients, flow triggering has been found to benefit auto PEEP. (3B) D. MANAGEMENT OF PATIENT ON NIV: D1. Sedation: Recommendations: A non-pharmacological approach to calm the patient (Reassuring the patient, proper environment) should always be tried before administrating sedatives. (UPP) In patients on NIV, sedation may be used with extremely close monitoring and only in an ICU setting with lookout for signs of NIV failure. (UPP) E. EQUIPMENT: Recommendations: We recommend that portable bilevel ventilators or specifically designed ICU ventilators with non-invasive mode should be used for delivering Non-invasive ventilation in critically ill patients. (UPP) Both critical care ventilators with leak compensation and bi-level ventilators have been equally effective in decreasing the WOB, RR, and PaCO2. (3B) Currently, Oronasal mask is the most preferred interface for non-invasive ventilation for acute respiratory failure. (3B) F. WEANING: Recommendations: We recommend that weaning from NIV may be done by a standardized protocol driven approach of the unit. (2B) How to cite this article: Chawla R, Dixit SB, Zirpe KG, Chaudhry D, Khilnani GC, Mehta Y, et al. ISCCM Guidelines for the Use of Non-invasive Ventilation in Acute Respiratory Failure in Adult ICUs. Indian J Crit Care Med 2020;24(Suppl 1):S61-S81.
32205957	60	85	Acute Respiratory Failure	Disease	MESH:D012131
32205957	104	109	ACUTE	Disease	MESH:D000208
32205957	110	144	HYPERCAPNIC RESPIRATORY FAILURE A1	Disease	MESH:D012131
32205957	146	151	Acute	Disease	MESH:D000208
32205957	168	172	COPD	Disease	MESH:D029424
32205957	227	232	acute	Disease	MESH:D000208
32205957	249	253	COPD	Disease	MESH:D029424
32205957	257	265	patients	Species	9606
32205957	271	276	acute	Disease	MESH:D000208
32205957	280	285	acute	Disease	MESH:D000208
32205957	297	317	respiratory acidosis	Disease	MESH:D000142
32205957	368	376	patients	Species	9606
32205957	382	387	acute	Disease	MESH:D000208
32205957	404	408	COPD	Disease	MESH:D029424
32205957	500	508	patients	Species	9606
32205957	592	595	NIV	Disease	
32205957	672	680	patients	Species	9606
32205957	686	691	acute	Disease	MESH:D000208
32205957	708	712	COPD	Disease	MESH:D029424
32205957	722	730	acidosis	Disease	MESH:D000138
32205957	760	763	ARF	Disease	
32205957	771	793	Chest wall deformities	Disease	MESH:D013898
32205957	794	816	Neuromuscular diseases	Disease	MESH:D009468
32205957	854	862	patients	Species	9606
32205957	866	869	ARF	Disease	
32205957	877	897	chest wall deformity	Disease	MESH:D013898
32205957	898	920	Neuromuscular diseases	Disease	MESH:D009468
32205957	937	940	UPP	Gene	7378
32205957	953	956	ARF	Disease	
32205957	964	996	Obesity hypoventilation syndrome	Disease	MESH:D010845
32205957	998	1001	OHS	Disease	MESH:D010845
32205957	1040	1044	AHRF	Disease	
32205957	1048	1051	OHS	Disease	MESH:D010845
32205957	1052	1060	patients	Species	9606
32205957	1084	1089	acute	Disease	MESH:D000208
32205957	1090	1101	hypercapnic	Disease	MESH:D012131
32205957	1105	1141	acute on chronic respiratory failure	Disease	MESH:D012131
32205957	1180	1185	obese	Disease	MESH:D009765
32205957	1187	1198	hypercapnic	Disease	MESH:D012131
32205957	1199	1207	patients	Species	9606
32205957	1213	1216	OHS	Disease	MESH:D010845
32205957	1230	1243	heart failure	Disease	MESH:D006333
32205957	1262	1270	acidosis	Disease	MESH:D000138
32205957	1273	1276	UPP	Gene	7378
32205957	1288	1293	ACUTE	Disease	MESH:D000208
32205957	1294	1303	HYPOXEMIC	Disease	MESH:D012131
32205957	1304	1323	RESPIRATORY FAILURE	Disease	MESH:D012131
32205957	1336	1341	Acute	Disease	MESH:D000208
32205957	1342	1353	Cardiogenic	Disease	MESH:D013575
32205957	1354	1370	Pulmonary Oedema	Disease	MESH:D011654
32205957	1420	1428	patients	Species	9606
32205957	1434	1437	ARF	Disease	
32205957	1446	1473	Cardiogenic pulmonary edema	Disease	MESH:D011654
32205957	1503	1511	patients	Species	9606
32205957	1517	1522	acute	Disease	MESH:D000208
32205957	1523	1536	heart failure	Disease	MESH:D006333
32205957	1538	1565	cardiogenic pulmonary edema	Disease	MESH:D011654
32205957	1664	1672	patients	Species	9606
32205957	1678	1705	cardiogenic pulmonary edema	Disease	MESH:D011654
32205957	1722	1726	BPAP	Chemical	-
32205957	1759	1786	cardiogenic pulmonary edema	Disease	MESH:D011654
32205957	1792	1803	hypercapnia	Disease	MESH:D006935
32205957	1821	1826	acute	Disease	MESH:D000208
32205957	1827	1836	hypoxemic	Disease	MESH:D012131
32205957	1837	1856	respiratory failure	Disease	MESH:D012131
32205957	1909	1915	oxygen	Chemical	MESH:D010100
32205957	1938	1943	acute	Disease	MESH:D000208
32205957	1944	1953	hypoxemic	Disease	MESH:D012131
32205957	1954	1973	respiratory failure	Disease	MESH:D012131
32205957	2084	2092	patients	Species	9606
32205957	2098	2103	acute	Disease	MESH:D000208
32205957	2104	2121	hypoxemic failure	Disease	MESH:D012131
32205957	2159	2162	ARF	Disease	
32205957	2170	2182	Chest Trauma	Disease	MESH:D013898
32205957	2220	2229	traumatic	Disease	MESH:D014947
32205957	2230	2241	flail chest	Disease	MESH:D005409
32205957	2262	2266	pain	Disease	MESH:D010146
32205957	2353	2361	patients	Species	9606
32205957	2373	2376	ARF	Disease	
32205957	2416	2422	oxygen	Chemical	MESH:D010100
32205957	2521	2528	dyspnea	Disease	MESH:D004417
32205957	2634	2642	patients	Species	9606
32205957	2648	2688	post-operative acute respiratory failure	Disease	MESH:D012131
32205957	2762	2770	patients	Species	9606
32205957	2776	2779	ARF	Disease	
32205957	2906	2914	patients	Species	9606
32205957	2933	2936	OSA	Disease	MESH:C535586
32205957	2940	2943	OHS	Disease	MESH:D010845
32205957	3073	3098	acute respiratory failure	Disease	MESH:D012131
32205957	3188	3196	patients	Species	9606
32205957	3229	3232	UPP	Gene	7378
32205957	3576	3584	patients	Species	9606
32205957	3588	3591	ARF	Disease	
32205957	3662	3679	Viral Pneumonitis	Disease	MESH:D014777
32205957	3680	3684	ARDS	Disease	MESH:D012128
32205957	3757	3765	patients	Species	9606
32205957	3771	3796	acute respiratory failure	Disease	MESH:D012131
32205957	3802	3816	H1N1 pneumonia	Species	
32205957	3871	3879	patients	Species	9606
32205957	3988	3993	Acute	Disease	MESH:D000208
32205957	4010	4032	Pulmonary Tuberculosis	Disease	MESH:D014397
32205957	4073	4081	patients	Species	9606
32205957	4087	4092	acute	Disease	MESH:D000208
32205957	4093	4105	Tuberculosis	Disease	MESH:D014376
32205957	4140	4149	infection	Disease	MESH:D007239
32205957	4257	4265	patients	Species	9606
32205957	4335	4343	patients	Species	9606
32205957	4433	4453	respiratory distress	Disease	MESH:D012128
32205957	4547	4567	respiratory distress	Disease	MESH:D012128
32205957	4597	4605	patients	Species	9606
32205957	4766	4773	patient	Species	9606
32205957	4820	4823	UPP	Gene	7378
32205957	4921	4928	patient	Species	9606
32205957	4965	4969	COPD	Disease	MESH:D029424
32205957	4970	4978	patients	Species	9606
32205957	5041	5054	MANAGEMENT OF	Disease	
32205957	5055	5065	PATIENT ON	Disease	
32205957	5145	5152	patient	Species	9606
32205957	5169	5176	patient	Species	9606
32205957	5255	5258	UPP	Gene	7378
32205957	5263	5271	patients	Species	9606
32205957	5386	5389	NIV	Disease	
32205957	5400	5403	UPP	Gene	7378
32205957	5605	5619	critically ill	Disease	MESH:D016638
32205957	5620	5628	patients	Species	9606
32205957	5631	5634	UPP	Gene	7378
32205957	5876	5901	acute respiratory failure	Disease	MESH:D012131
32205957	6202	6227	Acute Respiratory Failure	Disease	MESH:D012131

